CDC authorizes COVID-19 vaccines for children 5-11 years of age
Author
Blaire Bryant
Upcoming Events
Related News
Key Takeaways
On November 2, the Centers for Disease Control and Prevention (CDC) approved the use of COVID-19 vaccines for children aged 5-11 following the Food and Drug Administration’s (FDA) recommendation. The CDC’s endorsement follows the FDA’s recommendation on October 29 to authorize emergency use of the Pfizer-BioNTech COVID-19 vaccine to include children 5-11 years of age.
The FDA’s decision comes after it was determined the vaccine was approximately 91 percent effective in preventing COVID-19 in children 5-11 years of age. Children within this age group account for 39 percent of COVID-19 cases in individuals younger than 18 years of age across the nation. An ongoing study discovered no serious side effects in approximately 3,100 children aged 5-11 who received the COVID-19 vaccine.
On October 14, the CDC released a Pediatric COVID-19 Vaccination Operational Planning Guide, which highlights key differences between adult and adolescent vaccination programs and those that are designed for children. The National Association of County and City Health Officials (NACCHO) has provided a summary of the guide and pulled out high-level considerations for county health departments, as key components of pediatric COVID-19 vaccination planning in local communities.
As key providers of local public health services and frontline service providers for the medically vulnerable, counties have supported over 192 million vaccinations in the United States to date and will continue to play an essential role in the administration of COVID-19 vaccines and boosters. For more information on how county health facilities can prepare for the distribution of COVID-19 vaccines for children, and COVID-19 boosters, see NACo’s COVID-19 Vaccine Distribution Toolkit.
ADDITIONAL RESOURCES
Resource
COVID-19 Vaccine Toolkit for Counties
Related News
Michelle Alyssa Go Act reintroduced in the 119th Congress, a critical step for county behavioral health systems
On September 18, the Michelle Alyssa Go Act was reintroduced in the U.S. House of Representatives. This bipartisan legislation aims to increase the number of federal Medicaid-eligible in-patient psychiatric beds from 16 to 36, providing critical support for individuals seeking treatment for mental health and substance use disorders.
Congress passes SUPPORT Act reauthorization
On September 18, the U.S. Senate passed the SUPPORT for Patients and Communities Reauthorization Act of 2025 (SUPPORT Act Reauthorization) (H.R. 2483) by voice vote, following House passage earlier this year. With strong bipartisan backing in both chambers, the legislation now heads to the President’s desk for signature.
CMS releases Rural Health Transformation Program funding opportunity
On September 2, the Centers for Medicare & Medicaid Services (CMS) released additional details on the Rural Health Transformation (RHT) Program, overviewing program goals, requirements and timelines.